# Natalizumab administration in Relapsing Remitting Multiple Sclerosis
Keywords: Natalizumab, Relapsing Remitting Multiple Sclerosis, EASIER study, TYSABRI SC, adverse event reporting

> This page provides information about the administration of Natalizumab for Relapsing Remitting Multiple Sclerosis, including details on the EASIER study, adverse event reporting, and TYSABRI SC formulation.

## Details
- [The EASIER study](#): Overview of the study related to Natalizumab administration.
- [TYSABRI SC](#): Information on the subcutaneous formulation of TYSABRI.
- [TONiC-MS Study](#): Details about the TONiC-MS study related to Multiple Sclerosis.
- [SC vs IV real-world efficacy](#): Comparison of subcutaneous and intravenous efficacy in real-world scenarios.
- [Adverse event reporting](#): Guidance on reporting adverse events in the UK and Ireland.